WILMINGTON, Del. & KENILWORTH, N.J.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced additional details of their clinical development program investigating the combination of epacadostat, Incyte’s investigational oral selective IDO1 enzyme inhibitor, with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients across five tumor types: metastatic melanoma, non-small cell lung cancer (NSCLC), bladder cancer, renal cell carcinoma (RCC), and squamous cell carcinoma of the head and neck (SCCHN).
The expanded collaboration now includes seven pivotal studies:
- A Phase 3 study in metastatic melanoma (trial underway);
- two Phase 3 studies in first-line NSCLC, including both PD-L1 high-expressing and PD-L1 unselected populations;
- two Phase 3 studies in bladder cancer, including one in first-line bladder cancer and one in second-line bladder cancer;
- a Phase 3 study in first-line RCC; and
- a Phase 3 study in first-line SCCHN.
